Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysis

Life Sciences

Volumn 79, Issue 2, 2006, Pages 193-202

  Song, Ju Han ^a   Choi, Cheol Hee ^b   Yeom, Hye Jung ^c   Hwang, Seung Yong ^c   Kim, Tae Sung ^d  

^a Chonnam National University   (South Korea)

^b Chosun University   (South Korea)

^c Hanyang University   (South Korea)

^d Korea University   (South Korea)

Author keywords

DNA microarray; Doxorubicin; Leukemia; Resistance

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CATHEPSIN G; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 1; DAUNORUBICIN; DOXORUBICIN; GELATINASE A; MULTIDRUG RESISTANCE PROTEIN 1; STATHMIN; TUMOR NECROSIS FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG SENSITIVITY; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IKBKB GENE; LEUKEMIA CELL; LEUKEMIA CELL LINE; MCM5 GENE; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; ONCOGENE; PCNA GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA, COMPLEMENTARY; DNA, NEOPLASM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33646687085     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.12.054     Document Type: Article

References (43)

1. Balachandran R., Welsh M.J., and Day B.W. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene 22 55 (2003) 8924-8930
2. Bentires-Alj M., Barbu V., Fillet M., Chariot A., Relic B., Jacobs N., Gielen J., Merville M.P., and Bours V. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22 1 (2003) 90-97
3. Chaney S.G., and Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. Journal of the National Cancer Institute 88 19 (1996) 1346-1360
4. Chauncey T.R. Drug resistance mechanisms in acute leukemia. Current Opinion in Oncology 13 1 (2001) 21-26
5. Chen H., Sottile J., O'Rourke K.M., Dixit V.M., and Mosher D.F. Properties of recombinant mouse thrombospondin 2 expressed in Spodoptera cells. Jounal of Biological Chemistry 269 51 (1994) 32226-32232
6. Choi C.H., Kim H.S., Rha H.S., Jeong J.H., Park Y.H., Min Y.D., Kee K.H., and Lim D.Y. Drug concentration-dependent expression of multidrug resistance-associated protein and P-glycoprotein in the doxorubicin-resistant acute myelogenous leukemia sublines. Molecules and Cells 9 3 (1999) 314-319
7. Daschner P.J., Ciolino H.P., Plouzek C.A., and Yeh G.C. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Research and Treatment 53 3 (1999) 229-240
8. Devarajan E., Sahin A.A., Chen J.S., Krishnamurthy R.R., Aggarwal N., Brun A.M., Sapino A., Zhang F., Sharma D., Yang X.H., Tora A.D., and Mehta K. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 21 57 (2002) 8843-8851
9. Diah S.K., Smitherman P.K., Aldridge J., Volk E.L., Schneider E., Townsend A.J., and Morrow C.S. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Research 61 14 (2001) 5461-5467
10. Dolci E.D., Abramson R., Xuan Y., Siegfried J., Yuenger K.A., Yassa D.S., and Tritton T.R. Anomalous expression of P-glycoprotein in highly drug-resistant human KB cells. International Journal of Cancer 54 2 (1993) 302-308
11. El-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y., et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Research 54 5 (1994) 1169-1174
12. Ferrari D., Stepczynska A., Los M., Wesselborg S., and Schulze-Osthoff K. Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis. Journal of Experimental Medicine 188 5 (1998) 979-984
13. Friesen C., Fulda S., and Debatin K.M. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 11 11 (1997) 1833-1841
14. Gottesman M.M., Pastan I., and Ambudkar S.V. P-glycoprotein and multidrug resistance. Current Opinion in Genetics and Development 6 5 (1996) 610-617
15. Hofmann W.K., de Vos S., Elashoff D., Gschaidmeier H., Hoelzer D., Koeffler H.P., and Ottmann O.G. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 359 9305 (2002) 481-486
16. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 54 Suppl 4 (1997) 1-7
17. Hsiang Y.H., Hertzberg R., Hecht S., and Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. Journal of Biological Chemistry 260 27 (1985) 14873-14878
18. Kim H.S., Lee T.B., and Choi C.H. Down-regulation of catalase gene expression in the doxorubicin-resistant AML subline AML-2/DX100. Biochemical and Biophysical Research Communications 281 1 (2001) 109-114
19. Kim C.H., Kim J.H., Lee J., and Ahn Y.S. Zinc-induced NF-κB inhibition can be modulated by changes in the intracellular metallothionein level. Toxicology and Applied Pharmacology 190 2 (2003) 189-196
20. Knox P.G., Milner A.E., Green N.K., Eliopoulos A.G., and Young L.S. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. Journal of Immunology 170 2 (2003) 677-685
21. Kudoh K., Ramanna M., Ravatn R., Elkahloun A.G., Bittner M.L., Meltzer P.S., Trent J.M., Dalton W.S., and Chin K.V. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Research 60 15 (2000) 4161-4166
22. Lamendola D.E., Duan Z., Yusuf R.Z., and Seiden M.V. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Research 63 9 (2003) 2200-2205
23. Legrand O., Zittoun R., and Marie J.P. Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia 13 4 (1999) 578-584
24. Loe D.W., Deeley R.G., and Cole S.P. Biology of the multidrug resistance-associated protein, MRP. European Journal of Cancer 32A 6 (1996) 945-957
25. Marie J.P. Drug resistance in hematologic malignancies. Current Opinion in Oncology 13 6 (2001) 463-469
26. Maxwell P.J., Longley D.B., Latif T., Boyer J., Allen W., Lynch M., McDermott U., Harkin D.P., Allegra C.J., and Johnston P.G. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Research 63 15 (2003) 4602-4606
27. Misra S., Ghatak S., Zoltan-Jones A., and Toole B.P. Regulation of multidrug resistance in cancer cells by hyaluronan. Journal of Biological Chemistry 278 28 (2003) 25285-25288
28. Mitsiades N., Poulaki V., Kotoula V., Leone A., and Tsokos M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. American Journal of Pathology 153 6 (1998) 1947-1956
29. Mitsiades N., Yu W.H., Poulaki V., Tsokos M., and Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Research 61 2 (2001) 577-581
30. Moffatt P., and Denizeau F. Metallothionein in physiological and physiopathological processes. Drug Metabolism Reviews 29 1-2 (1997) 261-307
31. Nguyen D.M., Chen G.A., Reddy R., Tsai W., Schrump W.D., Cole Jr. G., and Schrump D.S. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. Journal of Thoracic and Cardiovascular Surgery 127 2 (2004) 365-375
32. Philip S., Bulbule A., and Kundu G.C. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. Journal of Biological Chemistry 276 48 (2001) 44926-44935
33. Prasad K.V., Ao Z., Yoon Y., Wu M.X., Rizk M., Jacquot S., and Schlossman S.F. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proceedings of the National Academy of Sciences of the United States of America 94 12 (1997) 6346-6351
34. Ritke M.K., Bergoltz V.V., Allan W.P., and Yalowich J.C. Increased c-Jun/AP-1 levels in etoposide-resistant human leukemia K562 cells. Biochemical Pharmacology 48 3 (1994) 525-533
35. Sakamoto M., Kondo A., Kawasaki K., Goto T., Sakamoto H., Miyake K., Koyamatsu Y., Akiya T., Iwabuchi H., Muroya T., Ochiai K., Tanaka T., Kikuchi Y., and Tenjin Y. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Human Cell 14 4 (2001) 305-315
36. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., and Peter M.E. Apoptosis signaling by death receptors. European Journal of Biochemistry 254 3 (1998) 439-459
37. Song J.H., Kim J.M., Kim S.H., Kim H.J., Lee J.J., Sung M.H., Hwang S.Y., and Kim T.S. Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sciences 73 13 (2003) 1705-1719
38. Staunton J.E., Slonim D.K., Coller H.A., Tamayo P., Angelo M.J., Park J., Scherf U., Lee J.K., Reinhold W.O., Weinstein J.N., Mesirov J.P., Lander E.S., and Golub T.R. Chemosensitivity prediction by transcriptional profiling. Proceedings of the National Academy of Sciences of the United States of America 98 19 (2001) 10787-10792
39. Wittig R., Nessling M., Will R.D., Mollenhauer J., Salowsky R., Munstermann E., Schick M., Helmbach H., Gschwendt B., Korn B., Kioschis P., Lichter P., Schadendorf D., and Poustka A. Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Research 62 22 (2002) 6698-6705
40. Yang J.M., Xu Z., Wu H., Zhu H., Wu X., and Hait W.N. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Molecular Cancer Research 1 6 (2003) 420-427
41. Young M.R., Yang H.S., and Colburn N.H. Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4. Trends in Molecular Medicine 9 1 (2003) 36-41
42. Zhao Y., You H., Yang Y., Wei L., Zhang X., Yao L., Fan D., and Yu Q. Distinctive regulation and function of PI 3K/Akt and MAPKs in doxorubicin-induced apoptosis of human lung adenocarcinoma cells. Journal of Cellular Biochemistry 91 3 (2004) 621-632
43. Zyad A., Benard J., Tursz T., Clarke R., and Chouaib S. Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression. Cancer Research 54 3 (1994) 825-831